Platinum rechallenge in recurrent head and neck squamous cell carcinoma after primary chemoradiation - 05/09/19

pages | 5 |
Iconographies | 2 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Objective |
To evaluate platinum rechallenge efficacy and tolerance in patients presenting recurrent head and neck squamous cell carcinoma (HNSCC) after platinum-based chemoradiation.
Materials and methods |
We retrospectively included all patients treated from 2007 to 2016 by platinum-based polychemotherapy for recurrence of HNSCC previously treated by primary or postsurgical platinum-based chemoradiation. The primary end-point was disease control rate (DCR) on platinum rechallenge.
Results |
Forty-five patients were included. Median disease-free interval (DFI) after chemoradiation was 5.7 months. DCR on platinum rechallenge was 40%. Progression-free survival at recurrence was 3.7 months and overall survival 5.0 months. DCR in patients with recurrence within 6 months of chemoradiotherapy was 47.8%. DFI>4.5 months was associated with better DCR: 28.5% versus 54.8%; P=0.0311.
Conclusion |
Platinum rechallenge provided good DCR in recurrent HNSCC after chemoradiation.
Le texte complet de cet article est disponible en PDF.Keywords : Head and neck cancer, Recurrence, Cisplatin, Carboplatin
Plan
Vol 136 - N° 4
P. 257-261 - septembre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?